.Nature Medicine, Published online: 09 October 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec received FDA authorization after an unfavorable trial, which highlights the numerous complexities and difficulties of medicine advancement within this environment.